Efficacy and Safety of Aflibercept 8 mg in PULSAR Trial in Neovascular AMD

Opinion
Video

Dr. Marion Munk reviews the Phase 3 clinical trial of high-dose aflibercept (8 mg) in neovascular AMD, emphasizing how this new therapy could alleviate the treatment burden for patients while providing superior outcomes.

Recent Videos
Chase Ludwig, MD, shared an overview of his presentation, which covered real-impact of vitrectomy surgery on the progression of AMD at the annual ASRS meeting in Stockholm, Sweden
Giulia Corradetti, MD, discusses her presentation "Functional Microperimetric Correlates of OCT Structures Features in Intermediate AMD"
Marion Munk, MD, PhD, presenting slides
Ash Abbey, MD, shares 36-month data from the GALE study of pegcetacoplan
Antonio Filipe Macedo, OD, MSc, PhD, speaks about the 2024 ARVO meeting
Kasperi Kankare at the iCare booth at ESCRS
Related Content
A cell being injected by a syringe. Image credit: ©Corona Borealis – stock.adobe.com

Trinity team’s gene therapy offers promising glaucoma and AMD treatment

Martin David Harp
September 9th 2024
Article

Research by investigators at Trinity College in Dublin, Ireland shows how the gene therapy conferred significant protection for retinal ganglion cells

The US FDA logo on a laptop screen. Image credit: ©monticellllo – stock.adobe.com

US FDA issues approval for Sandoz aflibercept-abzv (Enzeevu)

David Hutton
August 12th 2024
Article

The biosimilar is indicated to improve and maintain visual acuity for patients with neovascular age-related macular degeneration

Arrows hit a target on a yellow background. Image credit: ©MclittleStock – stock.adobe.com

VEGF-C and VEGF-D signaling pathways: Potential targets for treating wet AMD

Lynda Charters
July 11th 2024
Article

A novel formulation may prevent blood vessel growth and vascular leakage in the retina

An eye surrounded by digital interfaces and LEDs. AI generated. Image credit: ©aicandy – stock.adobe.com

Altos Biologics submits EMA Marketing Authorisation Application for aflibercept biosimilar ALT-L9

Sydney M Crago
July 3rd 2024
Article

Following the MAA in Europe, Altos Biologics plans to pursue approval in target markets including Korea

A person at a desk administers a stamp that says "approved." Image credit: ©H_Ko – stock.adobe.com

US FDA approves biosimilar aflibercept-mrbb (Ahzantive)

Martin David Harp
July 2nd 2024
Article

The drug is a biosimilar for aflibercept 2 mg (Eylea)

A close-up of an eye with light reflecting in the iris and the pupil. Image credit: ©PR ART – stock.adobe.com

Espansione Group receives CE Mark approval for eye-light® photobiomodulation device

Hattie Hayes
June 3rd 2024
Article

The flagship, light-based technology has received approval for applications in the anterior and posterior segments

© 2024 MJH Life Sciences

All rights reserved.